Position in ALMS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$24,497,220
-$2,237,242 QoQ
Shares Held
870,548
-28.3% QoQ
Ownership
0.673%
of shares outstanding
% of Portfolio
3.96%
of 13F equity value
Holder Rank
#28
of 196 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ALMS Over Time
Shares Held
Position Value (USD)
Derivatives in ALMS
reported options exposure · as of Jun 30, 2026CallValue
$10,026,282
CallShares
356,300
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Ikarian Capital, LLC holds $559,861,982 across 103 Biotechnology names. ALMS ranks #3 (4.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
328,635 | $43,793,900 | |
| 2 | KOD |
Kodiak Sciences Inc.
|
1,059,730 | $41,287,080 | |
| 3 | ALMS |
Alumis Inc.
This page
|
870,548 | $24,497,220 | |
| 4 | PRAX |
Praxis Precision Medicines, Inc.
|
72,842 | $24,386,773 | |
| 5 | PCVX |
Vaxcyte, Inc.
|
388,682 | $22,594,084 | |
| 6 | CLDX |
Celldex Therapeutics, Inc.
|
478,500 | $17,804,985 | |
| 7 | RCUS |
Arcus Biosciences, Inc.
|
504,559 | $15,555,553 | |
| 8 | RLMD |
Relmada Therapeutics, Inc.
|
2,148,359 | $14,866,644 |
All Filings in ALMS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10,026,282 | 356,300 | Call | Sole | 2026-08-14 | |
| 2026-06-30 | $24,497,220 | 870,548 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $26,734,462 | 1,213,548 | Shares | Sole | 2026-05-15 | |
| 2026-03-31 | $5,829,138 | 264,600 | Call | Sole | 2026-05-15 | |
| 2025-12-31 | $2,060,336 | 211,100 | Put | Sole | 2026-02-18 | |
| No filing history on record for this holder in this stock. | ||||||